Kolibri

Using sound to enable advanced therapies

Kolibri is a business in hard tech based in Ile de France, France, founded in 2021.

Profile

Kolibri is pioneering acoustic cell engineering to radically cut the cost and complexity of therapeutic manufacturing. Our patented platform supercharges existing bioproduction workflows, achieving 2x increase in AAV yields in both suspension and adherent cell systems using acoustic treatment, a promising development for scalability. 5x improvement in transfection rates in mesenchymal stem cells (MSCs), raising efficiency from 7.5% to 35%. 20x increase in plasmid usage efficiency, significantly reducing the potential cost per dose—an important economic lever given the high cost of plasmid reagents. These achievements translate to a 89% lower cost per dose than current chemical methods. We’ve secured five strategic partnerships from academia to large industry player to validate the tech across real-world settings.

Its activity falls under hard tech; the profile below is assembled from public directory data.

Ile de France, France is where the company is located.

Directory data places it at the SOSV portfolio company stage.

Its team size is recorded as 2-10 employees.

Total disclosed funding stands at about $1.9M.

Website: www.kolibrilab.com